Get the Stockscreener App
19.58
125.58%
10.90
Silence Therapeutics Plc Adr stock is traded at $19.58, with a volume of 44.83M.
It is up +125.58% in the last 24 hours and up +56.64% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$8.68
Open:
$19.585
24h Volume:
44.83M
Relative Volume:
35.11
Market Cap:
$1.22B
Revenue:
$840.00K
Net Income/Loss:
$-75.20M
P/E Ratio:
-12.30
EPS:
-1.5921
Net Cash Flow:
$-65.69M
1W Performance:
+98.58%
1M Performance:
+56.64%
6M Performance:
+157.63%
1Y Performance:
+197.12%
1-Day Range:
$19.57
$19.61
1-Week Range:
$8.66
$9.565
52-Week Range:
$4.19
$19.61
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
19.58 | 1.22B | 840.00K | -75.20M | -65.69M | -1.5921 |
VRTX
Vertex Pharmaceuticals Inc
|
505.83 | 128.21B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
228.58 | 91.26B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.36 | 81.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
823.17 | 51.77B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.27 | 41.77B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why - Zacks Investment Research
Silence Therapeutics at Cantor healthcare conference: divesiran advances By Investing.com - Investing.com South Africa
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Silence (SLN) Latest Quarter: The Report Provides a New Financial Snapshot for the Current Session; Investor Response: The Stock Gains 0.76% in Latest TradingEarnings Risk Report - dars.gov.et
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
What is HC Wainwright's Estimate for SLN Q3 Earnings? - MarketBeat
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEarnings Expansion Phase - careplusvn.com
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateRevenue Guidance Range - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateTech Earnings Analysis - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEstimate Revision Count - dars.gov.et
Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current UpdateEarnings Outlook Update - https://www.dars.gov.et/
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN) - MarketBeat
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com South Africa
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs - Business Wire
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Zacks Investment Research
Form 4: Griffiths Richard Ian reports acquisition/exercise transactions in SLN - Stock Titan
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentCore Business Growth - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentProfit Growth Outlook - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentMargin Expansion Trends - careplusvn.com
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentEarnings Forecast Report - dars.gov.et
SLN Q2 2026 Earnings: Net Loss of $0.26 per Share Highlights Ongoing Clinical-Stage InvestmentRevenue Estimate Trend - dars.gov.et
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - MarketBeat
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - Yahoo Finance
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares - Business Wire
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - MarketBeat
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
Silence Therapeutics (SLN) Rallies Ahead Of Key Phase 2 Data - timothysykes.com
Silence Therapeutics reports positive phase 2 trial results - Investing.com
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Finviz
Why is Silence Therapeutics stock surging today? By Investing.com - Investing.com South Africa
SLN Q4 2024 Earnings: Reports Positive EPS of $0.213138; Shares Move 1.96Profit Growth Outlook - careplusvn.com
SLN Q4 2024 Earnings: Reports Positive EPS of $0.213138; Shares Move 1.96Estimate Dispersion - dars.gov.et
Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year HighStill a Buy? - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
SLN Q4 2024 Earnings: EPS of $0.2131 Reported; Shares Decline 9.72Tech Earnings Analysis - vinanet.vn
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):